Ainos announced the results from its antiviral efficacy study in hamsters against the Omicron variant of SARS-CoV-2. The company’s results showed that its low-dose oral interferon alpha (“IFN-a”) formulation, VELDONA, had a therapeutic effect on lungs infected with the SARS-CoV-2 (the Omicron variant) virus by regulating the immune response, thus expediting recovery of infected animals. Plus the company has submitted the application documents for U.S. FDA Phase 2 clinical trials for evaluating the efficacy of VELDONA in patients with mild COVID-19.
The study evaluated the effectiveness of VELDONA over a 16-day course (5-day pre-treatment, one-day during viral infection and ten-day treatment after infection) of Omicron-variant-infected hamsters. Compared with hamsters in the placebo group receiving solution without VELDONA (the Placebo Group), the hamsters in the group receiving solution with VELDONA demonstrated resistance to body weight loss immediately after infection, then showed a better recovery trend in the following three days. The body weights of the hamsters in the VELDONA Group remained more stable than those of the hamsters in the Placebo Group during the treatment period.
News 
Market Data 
Discover 
